Dr. Reddy's Laboratories launches generic Bosutinib tablets in the United States

business-standard.com

Dr. Reddy's Laboratories launched generic Bosutinib Tablets 400 mg in the U.S., expanding its oncology offerings. The company secured exclusive marketing rights for the first-to-file product, developed and manufactured by MSN Laboratories, eligible for 180-day exclusivity. This launch aims to increase access to the cancer treatment, which had U.S. sales of approximately $253.8 million in the twelve months ending April 2026.


With a significance score of 2.9, this news ranks in the top 14% of today's 33772 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Dr. Reddy's Laboratories launches generic Bosutinib tablets in the United States | News Minimalist